Mutational Analysis of Driver and Non-driver Mutations of Philadelphia Chromosome-negative Myeloproliferative Neoplasms; Diagnosis and Recent Advances in Treatment
Table 5.
Clinical trials involving therapeuticagents as monotherapy or in combination with ruxolitinib (Adapted from: [81]).
|
| Agent |
MPN-subtype |
Mechanism of action |
Phase |
Clinical trial |
|
|
| LCL-161 |
Primary, post-PV or post-ET and MF |
IAPi |
II |
NCT02098161 |
|
| Navitoclax |
MF receiving ruxolitinib |
BCL-xLi |
II |
NCT03222609 |
|
| PU-H71 |
MF receiving ruxolitinib |
HSP-90i |
II |
NCT03935555 |
|
| Panobinostat |
MF receiving ruxolitinib |
HDACi |
Ib |
NCT01433445 |
|
| Idasanutlin |
Hydroxyurea intolerant PV, |
|
|
|
|
| ET and MF without prior |
|
|
|
|
|
| JAK2i |
MDM2 inhibitor |
I and II |
NCT03287245 and NCT02407080 |
|
|
| KRT-232 |
Phlebotomy-dependent PV, and MF with JAK2i failure |
MDM2 inhibitor |
II |
NCT03669965 and NCT03662126 |
|
| PRM-151 |
MF |
Pentraxin-2 inhibitor |
II |
NCT01981850 |
|
| Alisertib |
MF |
Aurora Kinase A inhibitor |
II |
NCT02530619 |
|
| Sotatercept |
PMF and MPN-associated anemia |
TGFβi |
II |
NCT01712308 |
|
| Luspatercept |
PMF and MPN-associated anemia |
TGFβi |
II |
NCT03194542 |
|
| AVID200 |
MF |
TGF-βi |
I/Ib |
NCT03895112 |
|
| Imetelstat |
MF with JAK2i |
Telomerase inhibitor |
II |
NCT02426086 |
|
| CPI-0610 |
MF |
BET inhibitor |
II |
NCT02158858 |
|
|
|
